A team from the University of Geneva has designed a molecular system that distinguishes and neutralises cancer cells with unprecedented precision, paving the way for autonomous, self-regulating drugs.
Using synthetic DNA strands, the smart system recognises cancer cells with exceptional precision and releases powerful drugs only where they are needed.
Beyond cancer treatment, this research paves the way to “smart” medicines and programmable drug delivery.
The corresponding article for the research is published in Nature Biotechnology.
Directly targeting cancer cells transforms therapy
The ability to directly target tumour cells with drugs is transforming cancer therapy, helping preserve healthy tissue and reducing the severe side effects associated with chemotherapy.
Amongst the most promising approaches of recent decades are antibody-drug conjugates (ADCs), which use monoclonal antibodies to deliver therapeutic agents precisely to cancer cells.
Despite their remarkable success, ADCs still face significant limitations, including poor penetration into tumour tissue and limited capacity to carry drug payloads.
DNA strands help overcome downfalls
In this new system, independent DNA strands carry distinct components, including two different cancer-targeting binders and a cytotoxic drug.
When two specific cancer markers bind to their respective DNA-linked binders, the components self-assemble precisely at the tumour site.
This assembly enables the delivery of higher drug concentrations, amplified by multiple DNA fragments snapping together where needed.
Similar to two-factor authentication on a banking website, this process only occurs when both cancer markers are present. If either marker is missing, the hybridisation chain reaction cannot initiate, and the drug remains inactive.
“This could mark an important step forward in the evolution of medicine, with the introduction of a self-operating drug system,” explained Nicolas Winssinger, full professor in the Department of Organic Chemistry of the School of Chemistry and Biochemistry, Faculty of Science, UNIGE.
“Until now, computers and AI have helped us design new drugs. What’s new here is that the drug itself can, in a simple way, ‘compute’ and respond intelligently to biological signals.”
The future of autonomous drugs
Just as computers are built on simple logic operations, “and”, “or”, “not”, this technology applies the same principle at the molecular level.
In this first demonstration, an “and” logic gate ensures activation only when two cancer biomarkers are present, making the drug highly selective.
In the future, future systems could integrate additional logic operations, creating medicines that behave like programmable systems and are capable of complex decision-making inside the body.
This opens the door to truly “smart” drugs that adapt to their environment, tailoring treatment to each patient’s unique physiology while minimising side effects.
Rather than replacing human oversight, these innovations aim to make therapies more targeted and effective, offering new hope for personalised care and transforming the way we combat disease.
Team Health Accessible
Health & Wellness Editorial Team
HealthAccessible editorial team delivers trusted, accessible, and evidence-based health information for everyone.
